Abstract: The invention relates to a device 1 for dosing and dry nebulization of nebulizable material 12 chosen from the group comprising anti-infective agents and immunomodulators, comprising a nebulization channel 3, which has a first attachment piece and a second attachment piece, and a source of compressed carrier gas connected to the first attachment piece via a valve 16 for the purpose of sending a carrier gas pressure pulse into the nebulization channel. The device is characterized in that between the first attachment piece and second attachment piece, and above the nebulization channel, a reservoir 10 open only towards the nebulization channel, which contains the nebulizable material 12, is connected to the nebulization channel such that it is gas-tight with respect to the environment, and that, when the valve is closed, a pressure compensation takes place in the nebulization channel and in the reservoir.

Abstract: The present invention is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container and closure are made of material which essentially does not release zinc ions.

Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.

Abstract: The invention relates to a method for investigating the modulating effect of a test substance on a PKC?-dependent signal transduction pathway or for finding a PKC? modulator in a human or animal cell, including the steps (a) contacting the cell with the test substance or with the PKC? modulator; (b) where appropriate inducing the kinase activity of PKC?; (c) incubating the cell under conditions which bring about phosphorylation at least of a serine or threonine residue of PKC?; (d) where appropriate lysing the cell; and (e) determining the phosphorylation content of the at least one serine or threonine residue of PKC?.

Abstract: The invention relates to novel processes for the preparation of high-purity roflumilast.

Abstract: The compounds of formula I in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

Abstract: The present invention relates to a method for the provision of clinical trial products in the context of clinical trials.

Abstract: The compounds of a certain formula (1), in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.

Abstract: The compounds of formula (I) in which R1, R11 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula I in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors.

Abstract: The invention relates to compounds of formula (I) which are effective inhibitors of histone deacetylases.

Abstract: The compounds of a certain formula (1), in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.

Abstract: The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases.

Abstract: The present invention relates to a method for the provision of clinical trial products and packaging of clinical trial products using RFID units in the context of clinical trials.

Abstract: The invention relates to a device (1) for dosing and dry nebulization of nebulizable material, comprising a nebulization channel (3), which has a first attachment piece and a second attachment piece, and a source of compressed carrier gas connected to the first attachment piece via a valve for the purpose of sending a carrier gas pressure pulse into the nebulization channel. The device is characterized in that between the first attachment piece and second attachment piece, and above the nebulization channel, a reservoir open only towards the nebulization channel, and used for receiving the nebulizable material, is connected to the nebulizaton channel such that it is gas-tight with respect to the environment, and that, when the valve is closed, a pressure compensation takes place in the nebulization channel and in the reservoir.

Abstract: The invention relates to novel processes for the preparation of high-purity roflumilast.

Abstract: The compounds of formula I in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.

Abstract: The invention relates to a process for the preparation of 16,17-[(cyclohexylmethylene)bis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione[11?,16?(R)] and similar compounds, by reaction of an appropriate 16,17-ketal with cyclohexanealdehyde.

Abstract: The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.